Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Griffith (Tyler, United States of America), R. Thomson (Brisbane, Australia), D. Addrizzo-Harris (New York, United States of America), S. Field (Calgary, Canada), J. Van Ingen (Nijmegen, Netherlands), C. Coulter (Brisbane, Australia), K. Mange (Bridgewater, United States of America), J. Nezamis (Bridgewater, United States of America), K. Winthrop (Portland, United States of America). Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study. 4951

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020 Isolation of M. abscessus from patients with M. avium complex (MAC) lung disease Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013 Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018 Treatment outcomes of macrolide-resistant mycobacterium avium complex lung disease Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017 Retrospective observation of mycobacterium avium complex lung disease followed without treatment Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019 Investigation of the inhibition of adherence of Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis (MTB) to the respiratory mucosa Source: Eur Respir J 2001; 18: Suppl. 33, 480s Year: 2001 Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009 A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis Year: 2006 Hospital-based antibiotic use in patients with Mycobacterium avium complex Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018 Year: 2018 Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017 Clinical utility of serum anti-mycobacterium avium complex (MAC) antibody for diagnosis of MAC lung disease in asymptomatic patients with radiologically suspected MAC lung disease: A pilot study Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015